Companies › Sichuan Luzhou Buchang Biopharmaceutical
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BC008-1A | – | Phase 1 | Glioma; Advanced Esophageal Cancers | Dec 2026 |
| BC001 G protein-coupled receptor β1 autoantibody antagonist | – | Phase 1 | Advanced or Metastatic Gastric Cancer | Apr 2027 |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Advanced or Metastatic Gastric Cancer | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06773481 | BC008-1A | Phase 1 | Glioma | Oncology | Dec 2026 |
| NCT06773312 | BC001 | Phase 1 | Advanced or Metastatic Gastric Cancer | Oncology | Apr 2027 |
| NCT06773312 | Sintilimab | Phase 1 | Advanced or Metastatic Gastric Cancer | Oncology | Apr 2027 |
| NCT06773507 | BC008-1A | Phase 1 | Advanced Esophageal Cancers | Oncology | Jun 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.